1. **Huang CY**, Lee KC, Tung SY, Huang WS, Teng CC, Lee KF, Hsieh MC\*, Kuo HC. 2D-DIGE-MS Proteomics Approaches for Identification of Gelsolin and Peroxiredoxin 4 with Lymph Node Metastasis in Colorectal Cancer. Cancers (Basel). 2022;14(13).
2. **Huang CY**, Huang WS, Chin CC, Kuo YH, Hsieh MC, Ho KC. Risk Factors for Mortality in Fournier’s Gangrene: Necrotizing Fasciitis in Perineum and Perianal Region, a Single-hospital Experience. J Soc Colon Rectal Surgeon (Taiwan) December 2021;32:97-104.
3. Lin CN, Huang WS, Huang TH, Chen CY, **Huang CY**, Wang TY, et al. Adding Value of MRI over CT in Predicting Peritoneal Cancer Index and Completeness of Cytoreduction. Diagnostics (Basel). 2021;11(4).
4. Cheng KC, Kuo HC, Hsieh MC, **Huang CY**, Teng CC, Tung SY, Shen CH, Lee KF, Yang YL, Lee KC. Identification of Two Novel CIL-102 Upregulations of ERP29 and FUMH to Inhibit the Migration and Invasiveness of Colorectal Cancer Cells by Using the Proteomic Approach. Biomolecules. 2021 Aug 27;11(9):1280.
5. Teng CC, Tung SY, Lee KC, Lee KF, Huang WS, Shen CH, Hsieh MC, **Huang CY**, Sheen JM, [Kuo](https://pubmed.ncbi.nlm.nih.gov/?term=Kuo+HC&cauthor_id=33246054) HC. Novel regulator role of CIL-102 in the epigenetic modification of TNFR1/TRAIL to induce cell apoptosis in human gastric cancer. Food Chem Toxicol. 2021 Jan;147:111856. Epub 2020 Nov 25.
6. Tung SY, Lee KC, Lee KF, Yang YL, Huang WS, Lee LY, Chen WP, Chen CC, Teng CC, Shen CH, Hsieh MC, **Huang CY**, Sheen JM, Kuo HC\*. Apoptotic mechanisms of gastric cancer cells induced by isolated erinacine S through epigenetic histone H3 methylation of FasL and TRAIL. Food Funct. 2021 Apr 21;12(8):3455-3468. Epub 2021 Mar 29.
7. Lee KF, Tung SY, Teng CC, Shen CH, Hsieh MC, **Huang CY**, Lee KC, Lee LY, Chen WP, Chen CC, Huang WS, Kuo HC. [Post-Treatment with Erinacine A, a Derived Diterpenoid of *H. erinaceus*, Attenuates Neurotoxicity in MPTP Model of Parkinson's Disease.](https://www.ncbi.nlm.nih.gov/pubmed/32033220) Antioxidants (Basel). 2020 Feb 4;9(2). pii: E137.
8. Kuo YH, Lai CH, **Huang CY**, Chen CJ, Huang YC, Huang WS, et al. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study. BMC Cancer. 2019 Aug 17;19(1):815.
9. Sun CY, Hsieh MC, Kuo LM, Chen CH, **Huang CY**, Huang WS\*. Single-incision Laparoscopic Surgery Using a Transumbilical Glove-port for Synchronous Colectomy and Hepatectomy: A Preliminary Experience in 9 Patients. J Soc Colon Rectal Surgeon (Taiwan) 2019 Mar;30(1):36-44.
10. Huang WS, **Huang CY**, Hsieh MC, Kuo YH, Tung SY, Shen CH, et al. Expression of PRDX6 Correlates with Migration and Invasiveness of Colorectal Cancer Cells. Cell Physiol Biochem. 2018;51(6):2616-30. (Co-First)
11. Ho KC, **Huang CY**, Chen CJ, Kuo YH\*, You JF, Chin CC, Huang WS. Preoperative Laboratory Neutrophil-lymphocyte Ratio, Serum Carcinoembryonic Antigen Level, and Serum Albumin Level Predict Overall Survival in Stage II Colon Cancer. J Soc Colon Rectal Surgeon (Taiwan) December 2018;29(4):168-179.
12. Kuo YH, Shi CS, **Huang CY**, Huang YC, Chin CC\*. Prognostic significance of unintentional body weight loss in colon cancer patients. Mol Clin Oncol 2018 Apr;8(4):533-538. Epub 2018 Feb 26.
13. Kuo YH, **Huang CY**, Chin CC, Chen CJ, Huang WS, You JF, Huang YC. Differential impacts of clinical variables and 5‑fluorouracil‑based adjuvant chemotherapy on 5‑year disease‑free survival of patients with stage IIa and IIb colon cancer.Formosan Journal of Surgery 2018;51(2):41-49.
14. Lee KC, Kuo HC, Shen CH, Lu CC, Huang WS, Hsieh MC, **Huang CY**, Kuo YH, Hsieh YY, Teng CC, Lee LY, Tung SY. A proteomics approach to identifying novel protein targets involved in erinacine A-mediated inhibition of colorectal cancer cells' aggressiveness. J Cell Mol Med. 2017 Mar;21(3):588-599.
15. Kuo HC, Kuo YR, Lee KF, Hsieh MC, **Huang CY**, Hsieh YY, Lee KC, Kuo HL, Lee LY, Chen WP, Chen CC, Tung SY. A Comparative Proteomic Analysis of Erinacine A’s Inhibition of Gastric Cancer Cell Viability and Invasiveness. Cell Physiol Biochem. 2017;43(1):195-208.
16. Huang WS, Kuo YH, Kuo HC, Hsieh MC, **Huang CY**, Lee KC, Lee KF, Shen CH, Tung SY, Teng CC. CIL-102-Induced Cell Cycle Arrest and Apoptosis in Colorectal Cancer Cells via Upregulation of p21 and GADD45. PLoS One. 2017;12(1):e0168989.
17. Kuo YH, **Huang CY**, Chen CJ, Hsu HC, Chuang HC, Lee TH, Hsieh MC, Huang WS, Chin CC\*. Impact of KRAS Mutation on Second-line Oxaliplatin-based (FOLFOX-6) Chemotherapy for Metastatic Colorectal Cancer. J Soc Colon Rectal Surgeon (Taiwan) 2017;28(1):34-42.
18. LuCC, Huang WS, Lee KF, Lee KC, Hsieh MC, **Huang CY**, Lee LY, Lee BO, Teng CC, Shen CH, Tung SY, Kuo HC. Inhibitory effect of Erinacines A on the growth of DLD-1 colorectal cancer cells is induced by generation of reactive oxygen species and activation of p70S6K and p21. Journal of Functional Foods 21 (2016) 474-484.
19. Huang WS,Hsieh MC, **Huang CY**, Kuo YH, Tung SY, Shen CH, Hsieh YY, Teng CC, Lee KF, Chen TC, Lee KC, Kuo HC. The Association of CXC Receptor 4 mediated signaling pathway with oxaliplatin-resistant human colorectal cancer cells. PLoS ONE. 2016; 11(9)
20. Huang WS, Lee TH, Chen CJ, Chin CC, Kuo YH, **Huang CY**. FAP Concurrent with Colon Cancer Managed by Total Proctocolectomy with Reverse Total Mesorectal Excision: A Case Report and Literature Review. J Soc Colon Rectal Surgeon (Taiwan) 2014;25:151-157.
21. Chen CJ, Chin CC, Kuo YH, **Huang CY**, Lee TH, Huang WS**\*.** Impact of Placement of Anal Tampon on Quality of In-patient Care in Stapled Hemorrhoidopexy Patients: Comparison Between Short-term Placement and Overnight Placement. J Soc Colon Rectal Surgeon (Taiwan) 2014;25:127-133.
22. **Huang CY**, Chin CC, Hsieh MC, Kuo YH, Huang WS, Yeh CH, Chen JS, Tang RP, Wang JY. The Relationship between the Presentation of Hematochezia and Colon Cancer. J Soc Colon Rectal Surgeon (Taiwan) December 2012;23:160-167.